Lacosamide Market

The global Lacosamide market size was valued at US$ 1.23 billion in 2024 and is projected to reach US$ 1.67 billion by 2030, at a CAGR of 5.2% during the forecast period 2024-2030.

United States Lacosamide market size was valued at US$ 401 million in 2024 and is projected to reach US$ 524 million by 2030, at a CAGR of 4.6% during the forecast period 2024-2030.

Antiepileptic drug used to treat partial-onset seizures.

Strong growth driven by increasing diagnosis of epilepsy and off-label use in neuropathic pain. Expanding indications supporting market expansion. Development of extended-release formulations improving patient compliance.

Report Overview
Lacosamide (INN, formerly known as erlosamide, harkeroside, SPM 927, or ADD 234037), is a medication for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. It is marketed under the trade name Vimpat.
Lacosamide Market provides a deep insight into the global Lacosamide market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Lacosamide Market, Lacosamide Market introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, Lacosamide Market is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Lacosamide market in any manner.
Global Lacosamide Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company

• UCB
• Teva
• Amneal Pharmaceuticals
• MSN Laboratories
• Alembic Pharma
• Glenmark
• Aurobindo Pharma
• Accord Healthcare
• Mylan
• Sun Pharma
• Apotex

• Oral tablets
• Oral solution
• Intravenous

• Adults
• Pediatric patients

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Lacosamide Market
• Overview of the regional outlook of the Lacosamide Market: